NephroPlus

NephroPlus said overseas markets now contribute nearly 42 per cent of revenue as the dialysis provider expands globally through acquisitions, PPP projects and clinic additions

Applicants can check their Nephrocare Health IPO allotment status on the official websites of NSE and BSE, or the registrar Kfin Technologies

India's largest dialysis provider plans to expand clinics at home and abroad ahead of its December 10 IPO, betting on rising CKD burden and demand for accessible dialysis care

IPO-bound NephroCare Health Services Ltd on Friday announced the acquisition of five new dialysis clinics in the Philippines, bringing its total footprint in the country to 39. The newly acquired clinics include Santiago, Isabela Dialysis Center, Cabuyao, Laguna Dialysis Center, Binondo, Manila Dialysis Center, CP Garcia Ave, Diliman, Quezon City Dialysis Center and E Rodriguez, Quezon City Dialysis Center. The Hyderabad-based company entered the Philippines market in fiscal 2020 and has since expanded rapidly, growing from 3,614 treatments per month in fiscal 2021 to 22,073 treatments per month in fiscal 2025. "This expansion marks a milestone in our journey in the Philippines, which has now become one of our key countries of operations after India," Rohit Singh, Group CEO of NephroCare Health Services, said in a statement. NephroCare Health Services, known for its NephroPlus brand, initially expanded into the Philippines by acquiring a majority stake in Royal Care Dialysis Clinic

The Hyderabad based firm aims to raise ₹353.4 crore through a fresh issue of equity shares. Market sources claim the total issue size could touch ₹2000 crore

All you need to know before the Indian stocks open for trade on Friday: GIFT Nifty hints quiet start. Nephro Care India will be the first SME IPO to debut after Sebi announced a cap on listing price.

Founded in 2010, NephroPlus currently operates about 450 dialysis centres across three main countries: India, the Philippines, and Uzbekistan

"The transaction will support NephroPlus in serving the growing demand for high quality, affordable dialysis services across India and other markets in Asia," Singapore-headquartered Quadria said

Healthcare provider will use the proceeds to set up a hospital in Kolkata and for general corporate purposes

Nephrocare India, a Kolkata-based comprehensive renal care institution, has raised Rs 8.08 crore in its pre-IPO round paving the way for its expansion plans, the company said on Friday. The funding saw participation from marquee investors, who include former HDFC chairman Deepak Parekh, HDFC Securities chairman Bharat Shah, and founder and MD of Macleods Pharmaceuticals Rajendra Agarwal, it said. The fresh infusion of capital will fuel Nephrocare India's target of establishing 22 high-end kidney care facilities across India by March 2026. Four centres are expected to be operational by the end of the current fiscal, the company said in a statement. Its long-term vision is to establish 300 Nephrocare centres across the country within the next 8-10 years. Highlighting the critical need for such expansion, company officials pointed out the vast demand for kidney care units in India, the statement said. With an estimated seven crore patients struggling with chronic kidney diseases and

Series E round was round led by IIFL Asset Management, with support from existing investors InvestCorp and Bessemer Venture Partners

NephroPlus recently received an investment of $45 million (Rs 323 crore)from Investcorp of Bahrain

NephroPlus' will use the primary capital raised in this round for organic growth in India and to take its business model to other markets, starting with Southeast Asia

The company plans to open 400 more centres in the next five years, primarily through partnership with hospitals

The new infusion of funds will be used to meet the growing need for kidney disease management services in the country, the company said

Touted to be the country's largest dialysis provider network with 75 centres across 15 states